Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Significant Decline in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 597 shares, a drop of 60.3% from the June 15th total of 1,503 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 3,169 shares, the days-to-cover ratio is currently 0.2 days.

Santen Pharmaceutical Stock Down 5.0%

Shares of SNPHY traded down $0.69 during trading hours on Tuesday, reaching $13.12. 702 shares of the company traded hands, compared to its average volume of 11,785. The business has a fifty day moving average price of $12.18 and a 200-day moving average price of $11.39. Santen Pharmaceutical has a 12-month low of $9.22 and a 12-month high of $13.93. The stock has a market capitalization of $4.23 billion and a P/E ratio of 0.10.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold”.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.